STI571: Targeting BCR-ABL as therapy for CML

Oncologist

Volumn 6, Issue 3, 2001, Pages 233-238

  Mauro, Michael J ^a,b   Druker, Brian J ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Chronic myelogenous leukemia; Philadelphia chromosome; STI571; Tyrosine kinase

Indexed keywords

BCR ABL PROTEIN; IMATINIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; TYROSINE KINASE RECEPTOR;

AREA UNDER THE CURVE; ARTICLE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CYTOGENETICS; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS; GENES, ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PYRIMIDINES;

EID: 0034951384     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-3-233     Document Type: Article

References (24)

1. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia
2. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors
3. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
4. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor
5. Clinical efficacy and safety of an ABL specific tyrosine kinase inhibitor as targeted therapy for chronic myelogenous leukemia
6. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia
7. Activity of an Abl specific tyrosine kinase inhibitor in patients with Bcr-Abl positive acute leukemias, including chronic myelogenous leukemia in blast crisis
8. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
9. +CML)
10. A phase II study of STI571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase
11. A phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis
12. Induction of resistance to the Abelson inhibitor STI571 in human leukemia cells through gene amplification
13. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines
14. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: Diverse mechanisms of resistance
15. + leukemia patients treated with an Abl-specific kinase inhibitor is associated with reactivation of Bcr-Abl
16. Role of α1 acid glycoprotein in the in vivo resistance of human BCR-ABL + leukemia cells to the ABL inhibitor STI571
17. Efficacy of STI571, an ABL tyrosine kinase inhibitor in conjunction with other anti-neoplastic agents against BCR-ABL positive cells
18. Gastrointestinal pacemaker cell tumor (GIPACT): Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal
19. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors
20. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors
21. Effects of tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor
22. STI571, an active drug in metastatic gastro intestinal stromal tumors (GIST), an EORTC phase I study
23. Evaluation of the safety and efficacy of an oral molecularly-targeted therapy, STI571, in patients with unresectable or metastatic gastrointestinal stromal tumors (GISTS) expressing c-kit (CD117)
24. Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class